Busey Bank Purchases 55,380 Shares of Novo Nordisk A/S (NYSE:NVO)

Busey Bank increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 108.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 106,434 shares of the company’s stock after buying an additional 55,380 shares during the period. Busey Bank’s holdings in Novo Nordisk A/S were worth $9,155,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Xponance Inc. boosted its position in shares of Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after purchasing an additional 576 shares in the last quarter. AQR Capital Management LLC lifted its stake in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after buying an additional 9,012 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Novo Nordisk A/S by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock worth $18,824,000 after buying an additional 2,817 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of Novo Nordisk A/S by 9.5% in the 2nd quarter. Cetera Investment Advisers now owns 290,845 shares of the company’s stock valued at $41,515,000 after acquiring an additional 25,307 shares in the last quarter. Finally, New Century Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $247,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.3 %

NVO stock opened at $84.05 on Thursday. The stock’s 50 day moving average is $94.75 and its 200-day moving average is $114.02. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The firm has a market capitalization of $377.17 billion, a PE ratio of 27.20, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.